In prostate cancer, a CSC population with the CD44+/integrinα2β1hi/CD133+ phenotype has been identified that exhibits extensive proliferation, self-renewal, differentiation, and invasion (Collins et al, 2005). Here, CD44 is linked to prostate carcinoma.